NASDAQ NMS - GLOBAL MARKET · HRMY
+0.24% · +$0.0900 · Vol Not reported
Pre-market · updated 04:27:52 ET
Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Pharmaceuticals
$38.24
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Analyst data unavailable at compute time · Sentiment absence reason unknown
HRMY
Harmony Biosciences Holdings Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

68/ 100
Veridion Score
BUY BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is HRMY moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading HRMY catalysts
About Harmony Biosciences Holdings Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
293
Country
US

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$38.15
Last session
Day high
$38.15
Last session
Day low
$38.15
Last session
Previous close
$38.15
52W high
$40.51
-5.60% from high
52W low
$25.90
84% of range
Market cap
$2.2B
P/E
11.31×
EPS
$3.38
Beta
0.11
Shares out
58.2M
Avg volume
834.5K
VWAP
$38.15
Last session
Price history computed in-house
1W
+0.26%
1M
+8.27%
3M
+27.09%
1Y
+1.00%
YTD
+2.19%
SMA 50 $36.30 · above
SMA 200 $33.84 · above
52W position 84%

HRMY overview

Veridion Score
68
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around HRMY.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading HRMY Form 4 filings
Public disclosures

Congress activity in HRMY

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for HRMY in the cached public ledger.

Federal contracts

HRMY contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for HRMY in this window.
Lobbying spend

HRMY lobbying filings, year to date.

Registered lobbying filings matched to Harmony Biosciences Holdings Inc.

$640.0K
Refresh interval: 12hSource: LDA disclosure filings
PharmacyHealth Issues
Filing
$180.0K
HARMONY BIOSCIENCES

HARMONY BIOSCIENCES

Jul 20, 2026
Filing
$180.0K
HARMONY BIOSCIENCES

HARMONY BIOSCIENCES

Apr 14, 2026
Filing
$180.0K
HARMONY BIOSCIENCES

HARMONY BIOSCIENCES

Jan 19, 2026
Loading news for HRMY
Analyst ratings
Sovereign unlock shows live analyst consensus for HRMY.
Options
Sovereign unlock shows live options positioning for HRMY.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.